Why the First Generic Drug Filer Gets 180 Days of Market Exclusivity
The first generic drug company to file an ANDA with a Paragraph IV certification gets 180 days of exclusive market rights under the Hatch-Waxman Act. This incentive drives competition but has been exploited to delay generic access.
Read More